DOP2009000130A - Sal de potasio cristalina de analogos de lipoxina a4 - Google Patents

Sal de potasio cristalina de analogos de lipoxina a4

Info

Publication number
DOP2009000130A
DOP2009000130A DO2009000130A DO2009000130A DOP2009000130A DO P2009000130 A DOP2009000130 A DO P2009000130A DO 2009000130 A DO2009000130 A DO 2009000130A DO 2009000130 A DO2009000130 A DO 2009000130A DO P2009000130 A DOP2009000130 A DO P2009000130A
Authority
DO
Dominican Republic
Prior art keywords
potassium salt
lipoxine
crystal potassium
analog crystal
crystalline potassium
Prior art date
Application number
DO2009000130A
Other languages
English (en)
Spanish (es)
Inventor
Tilo Haag
Danja Grossbach
Gabriele Winter
Michael Sander
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2009000130(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of DOP2009000130A publication Critical patent/DOP2009000130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
DO2009000130A 2006-12-04 2009-06-04 Sal de potasio cristalina de analogos de lipoxina a4 DOP2009000130A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
DOP2009000130A true DOP2009000130A (es) 2009-08-15

Family

ID=39076610

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000130A DOP2009000130A (es) 2006-12-04 2009-06-04 Sal de potasio cristalina de analogos de lipoxina a4

Country Status (28)

Country Link
US (2) US7906678B2 (enExample)
EP (2) EP3489214A1 (enExample)
JP (1) JP5410984B2 (enExample)
KR (3) KR20090101169A (enExample)
CN (1) CN101553456B (enExample)
AR (1) AR064116A1 (enExample)
AU (1) AU2007327765B2 (enExample)
BR (1) BRPI0719679A2 (enExample)
CA (1) CA2670791C (enExample)
CL (1) CL2007003468A1 (enExample)
CO (1) CO6190608A2 (enExample)
CR (1) CR10837A (enExample)
DO (1) DOP2009000130A (enExample)
EA (1) EA018615B1 (enExample)
EC (1) ECSP099380A (enExample)
IL (1) IL198434A (enExample)
MA (1) MA31079B1 (enExample)
MX (1) MX2009005911A (enExample)
MY (1) MY147951A (enExample)
NO (1) NO20092528L (enExample)
NZ (1) NZ577338A (enExample)
PE (2) PE20120395A1 (enExample)
SV (1) SV2009003286A (enExample)
TN (1) TN2009000167A1 (enExample)
TW (1) TWI415833B (enExample)
UY (1) UY30755A1 (enExample)
WO (1) WO2008068041A1 (enExample)
ZA (1) ZA200904689B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906678B2 (en) * 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
CN102470158A (zh) * 2009-08-27 2012-05-23 默沙东公司 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
EP2958560B1 (en) * 2013-02-21 2019-05-08 Forsyth Dental Infirmary for Children Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs
ES2895062T3 (es) * 2015-03-18 2022-02-17 Forsyth Dental Infirmary For Children Métodos para estabilizar placas ateroscleróticas usando lipoxinas, resolvinas y análogos de las mismas
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2020507761A (ja) 2017-01-31 2020-03-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症系疾患の生化学的エンドタイプを定義するａｌｘ受容体リガンド
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
WO1994029262A1 (en) 1993-06-15 1994-12-22 Brigham & Women's Hospital Lipoxin compounds
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
WO2000054767A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
TR200201244T2 (tr) 1999-11-09 2002-08-21 Alcon, Inc. Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
JP2005516011A (ja) 2001-12-13 2005-06-02 ランバクシー ラボラトリーズ リミテッド 結晶二水化セフニディールカリウム
JP4634716B2 (ja) 2002-03-15 2011-02-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形
DE602004029982D1 (de) 2003-01-30 2010-12-23 Lek Pharmaceuticals Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
KR20070088764A (ko) 2005-10-31 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 세프디니어 칼륨염의 결정형
US7906678B2 (en) * 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs

Also Published As

Publication number Publication date
PE20081200A1 (es) 2008-11-06
EP2089350B1 (en) 2018-08-22
JP5410984B2 (ja) 2014-02-05
CL2007003468A1 (es) 2008-07-04
AU2007327765A1 (en) 2008-06-12
IL198434A (en) 2012-09-24
EA200900732A1 (ru) 2009-12-30
MX2009005911A (es) 2009-09-07
CR10837A (es) 2009-07-23
NO20092528L (no) 2009-08-26
CN101553456B (zh) 2013-08-28
US8049035B2 (en) 2011-11-01
CA2670791C (en) 2017-01-03
EP3489214A1 (en) 2019-05-29
TN2009000167A1 (en) 2010-10-18
CO6190608A2 (es) 2010-08-19
ECSP099380A (es) 2009-11-30
SV2009003286A (es) 2009-10-02
US20080182897A1 (en) 2008-07-31
ZA200904689B (en) 2011-10-26
US7906678B2 (en) 2011-03-15
CN101553456A (zh) 2009-10-07
KR20090101169A (ko) 2009-09-24
TWI415833B (zh) 2013-11-21
MY147951A (en) 2013-02-15
KR20140135847A (ko) 2014-11-26
UY30755A1 (es) 2008-07-31
TW200838847A (en) 2008-10-01
CA2670791A1 (en) 2008-06-12
WO2008068041A1 (en) 2008-06-12
KR20160054030A (ko) 2016-05-13
BRPI0719679A2 (pt) 2014-01-14
MA31079B1 (fr) 2010-01-04
NZ577338A (en) 2011-02-25
JP2010511649A (ja) 2010-04-15
AR064116A1 (es) 2009-03-11
EP2089350A1 (en) 2009-08-19
PE20120395A1 (es) 2012-05-23
US20110124910A1 (en) 2011-05-26
EA018615B1 (ru) 2013-09-30
HK1135961A1 (en) 2010-06-18
AU2007327765B2 (en) 2012-04-12
IL198434A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
DOP2009000130A (es) Sal de potasio cristalina de analogos de lipoxina a4
ECSP12012026A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GT201000211A (es) Procesos e intermediarios para la preparación de derivados de acido 5-bifenil-a-il-2-metilpentanoico
BR112015001618A2 (pt) composições fungicidas
CU23848B1 (es) Derivados de octahidrofenantreno n(2-metilpiridino-3-il) carboxamida útiles como moduladores de receptor de glucocorticoides
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
AR079152A1 (es) Inhibidores de glucosilceramida sintasa
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
BRPI1014802B8 (pt) profármacos de triptolida.
CR20120268A (es) Método para reducir el estrés por temperatura de plantas
UY32622A (es) Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
UY29791A1 (es) Sales novedosas de lisina de derivados de acido 4-( (fenoxialquil)tio)-fenoxiacetico
BR112012012903A2 (pt) compostos de espiropiperidina
BRPI0817747A8 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
UY31738A (es) Inhibidores a base de hidroxamato de desacetilasas b
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
BRPI0514766A (pt) composições farmacêuticas
BR112014014877A2 (pt) derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2021001640A1 (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
BRPI0607093A2 (pt) polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende
BR112012009292A2 (pt) processo para preparação do composto, sal de potássio, solvato de acetona, forma cristalina, e, composto
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
BRPI0607092A2 (pt) polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende